Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Verily

Biotech & Life Sciences · San Francisco, United States · Founded 2015 Unicorn

Develops tools and devices to collect, organize and activate health data

Valuation
$1–2.5B
Latest valuation · Mar/2026
Unlock exact value
Headcount
1–2k
Current team size
Unlock exact value

Investors

7 investors on Verily's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage
Temasek
Series X Capital
Silver Lake Partners
Alphabet | Google
University of Colorado Anschutz Medical Campus
UCHealth
Ontario Teachers’ Pension Plan

Global footprint

Where Verily has talent and traffic

AI talent share
4.0% of workforce is AI talent
(50 of 1,254 staff)
Core AI231.83%
Other AI272.15%
Non-AI workforce1,20496.01%
Workforce by country
16 countries with
team presence
🇺🇸 United States89%
🇨🇦 Canada7.5%
🇸🇬 Singapore1.7%
🇮🇳 India0.3%
🇮🇱 Israel0.3%
Top 5 of 16 shown
Web traffic by country
71K monthly visits
across markets
🇺🇸 United States53%
🇨🇦 Canada15.2%
🇮🇳 India10.4%
🇦🇺 Australia3.5%
🇬🇧 United Kingdom3.2%
Top 5 markets shown

Patent intelligence

$283M patent portfolio · 760 active families

Estimated portfolio value
$283M
15.7% of valuation · 3.3× smaller than top peer Globus Medical ($930M)
760 active patent families
Where Verily innovates Biomedical engineeringOptometryMechanical engineeringPhysicsOphthalmology

Where Verily concentrates vs peers

Each axis is a top-10 topic across Verily and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Verily's 13 investments and acquisitions.

Every disclosed deal where Verily appeared as a backer or acquirer, 2017–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

13 deals across Verily's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Verily deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Verily's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        13 of 13 deals

        Market sentiment

        What the market is saying about Verily

        An AI-synthesized read of the highest-engagement posts about Verily on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Verily on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.